Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based XTL Biopharmaceuticals has appointed David Grossman and Boaz Shweiger to its board of directors.
Subscribe to our email newsletter
In addition, Mr Grossman will also be assuming the role of co-CEO, with no remuneration, to assist in XTL’s analysis of its strategic alternatives.
Mr Grossman served as a vice president of Eurocom Investments, a private equity fund focused on long-term investments mainly in Israeli public companies, from March 2006 to December 2008. Mr Grossman has received a BA business administration with a focus on information technology, from the Interdisciplinary Center Herzliya.
Mr Shweiger has served as a partner and managing director of Sean Holdings, a private investment company, since August 2005. Mr Shweiger has received an LLB, magna cum laude, from the College of Management and an MBA in finance and auditing from Tel-Aviv University.